Teladoc Health, a virtual care company, announced at the HLTH Conference on Tuesday that it is giving employers a new option to contribute toward the cost of GLP-1 medications outside of traditional pharmacy benefits.
The New York City-based company offers virtual medical care, mental health, chronic condition management and other services.
The new offering allows employers to help their employees access FDA-approved GLP-1 medications from both Eli Lilly and Novo Nordisk. With the offering, employers set a fixed contribution per employee per fill for each plan year. Employees then pay the remaining balance.
Teladoc handles eligibility and program oversight of the GLP-1 benefit and employers have transparency into what they pay for each fill, according to the announcement. Employers may also link their contributions to participant engagement, requiring activities such as food tracking, regular weigh-ins and completing educational content to qualify for employer funding.
This comes as about half of employers don’t cover GLP-1s for weight loss, according to WTW.
“We built this in response to what we’re hearing from our clients and markets broadly,” said Kelly Bliss, Teladoc Health’s president of U.S. Group Health. “Determining GLP-1 coverage for obesity is one of the hardest benefits decisions employers have faced in decades. Some cover these treatments with few restrictions, others have made the difficult decision not to cover them at all, and most fall somewhere in the middle. Employers don’t want an all-or-nothing approach to GLP-1s, and they shouldn’t have to settle for one.”
She added that this new offering also gives employers more predictability into their GLP-1 spend, which has been a major challenge for employers in recent years. The employer contribution option is already available for employer clients, and the first contracted clients will launch their programs starting January 1.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
In addition to GLP-1 support, patients also gain guidance from obesity medicine clinicians, registered dietitians and health coaches through Teladoc.
“Medication is only part of the answer,” Bliss said. “GLP-1s are a game changer for many people, but without counseling and provider oversight, people may start them without understanding the side effects, and the results may not last. … Our care teams stay with people over time, helping them manage nutrition, activity, sleep and stress. For employers, ongoing support is the difference between paying for prescriptions and paying for results.”
Photo: Jason Dean, Getty Images